Sterling Investment Advisors (Pennsylvania)’s Grace Therapeutics GRCE Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-833	Closed	-$4K	–	551
2022 Q2	$4K	Hold	833	–	–	﹤0.01%	471
2022 Q1	$6K	Hold	833	–	–	﹤0.01%	485
2021 Q4	$6K	Hold	833	–	–	﹤0.01%	480
2021 Q3	$10K	Hold	833	–	–	﹤0.01%	439
2021 Q2	$22K	Hold	833	–	–	0.01%	346
2021 Q1	$24K	Hold	833	–	–	0.01%	318
2020 Q4	$13K	Hold	833	–	–	﹤0.01%	348
2020 Q3	$8K	Hold	833	–	–	﹤0.01%	363
2020 Q2	$18K	Hold	833	–	–	0.01%	309
2020 Q1	$15K	Buy	833 +416	+100%	+$14.7K	0.01%	294
2019 Q4	$49K	Hold	417	–	–	0.02%	213
2019 Q3	$38K	Buy	+417	New	+$38.6K	0.02%	234

Other funds holding GRCE

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s GRCE Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Grace Therapeutics (GRCE) in Q3 2022, closing a stake of 833 shares — an estimated $4K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in GRCE in Q3 2019 and held it in 12 quarters. The position peaked at $49K in Q4 2019. 9 funds tracked by Wall St. Rank hold GRCE as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining Grace Therapeutics position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 833 Grace Therapeutics shares in Q3 2022, an estimated $4K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Grace Therapeutics in Q3 2019 and held it in 12 quarters.
Sterling Investment Advisors (Pennsylvania)'s Grace Therapeutics position peaked at $49K in Q4 2019.
9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.